UK

The expansion also aligns with the government’s National Cancer Plan for England, which focuses on accelerating patient diagnosis and improving access to treatment nationwide.

The company plans to utilize two key facilities for this production: its Oxford, United Kingdom site and its Durham, North Carolina location.

The company will showcase its technology on the ABHI UK Pavilion alongside a robust delegation of UK life sciences and health technology companies.

The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.

Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.

With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.

The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.

This oral formulation offers a more convenient delivery method compared to intravenous treatments.